This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

HomeBrowseAboutFAQs
Log In
Sign Up
Hodgkin Lymphoma
+1

CD30 Targeted CAR-T in Treating CD30-Expressing Lymphomas

Sponsored by Immune Cell, Inc.

About this trial

Last updated 7 years ago

Study ID

CD30-targeting CAR-T

Status

Recruiting

Type

Interventional

Phase

Phase 1

Placebo

No

Accepting

18-75 Years
2 to 80 Years
All
All

Not accepting

Not accepting
Healthy Volunteers

Trial Timing

Started 8 years ago

What is this trial about?

CAR-T cells have been validated effective in treating CD19 positive B cell lymphoma. Other lymphomas like Hodgkin's lymphoma and anaplastic large cell lymphoma are CD30 positive. In this study, a newly CD30 targeted CART therapy ICAR30 is designed to specifically kill those CD30 expressing malignancies including Hodgkin's lymphoma and CD30+ anaplastic large cell lymphoma. The subjects will receive several doses of autologous ICAR30 T cells infusion and then the safety, treating effects and lasting period of these cells in vivo will be evaluated.

What are the participation requirements?

Yes

Inclusion Criteria

Hodgkin's lymphoma, anaplastic large cell lymphoma and other CD30 positive malignancies, relapsed or refractory: - Karnofsky or Lansky score >50; - Expected survival>12 weeks; - Hgb > 8.0; - FEV1, FVC and DLCO ≥50% of expected corrected for hemoglobin; - LVEF≥50%; - Creatinine<2.5mg/dl; - Bilirubin<2.5mg/dl; - ALT (alanine aminotransferase)/AST (aspartate aminotransferase)<3 fold normal; - Patients must sign an informed consent.

No

Exclusion Criteria

- Pregnant or lactating; - Uncontrolled active infection including hepatitis B or C; - HIV positive; - Active clinically significant CNS dysfunction; - Current use of systemic steroids; - Heterogenous lymphocyte treatments within recent 6 months;

Locations

Location

Status

Recruiting